Clinical Trials Browser

Metastatic Solid Tumors × tislelizumab × Gastrointestinal × Clear all

NCT06585488 2026-06-03

A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification

Phase 1 Terminated

GastrointestinalOther solid neoplasmThoracic

Metastatic Solid Tumors